Safety and Efficacy of Blinatumomab in Japanese Adult and Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Final Results from an Expansion Cohort | Zendy

Hiroaki Goto | Zendy; Chitose Ogawa | Zendy; Hiroatsu Iida | Zendy; Keizo Horibe | Zendy; Iekuni Oh | Zendy; Satoru Takada | Zendy; Yoshinobu Maeda | Zendy; Hironobu Minami | Zendy; Yasuhiro Nakashima | Zendy; Joan Morris | Zendy; William Kormany | Zendy; Yuqi Chen | Zendy; Toshihiro Miyamoto | Zendy

Open Access

Safety and Efficacy of Blinatumomab in Japanese Adult and Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Final Results from an Expansion Cohort

Author(s) -

Hiroaki Goto,

Chitose Ogawa,

Hiroatsu Iida,

Keizo Horibe,

Iekuni Oh,

Satoru Takada,

Yoshinobu Maeda,

Hironobu Minami,

Yasuhiro Nakashima,

Joan Morris,

William Kormany,

Yuqi Chen,

Toshihiro Miyamoto

Publication year - 2022

Publication title -

acta haematologica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.574

H-Index - 56

eISSN - 1421-9662

pISSN - 0001-5792

DOI - 10.1159/000525835

Subject(s) - blinatumomab , refractory (planetary science) , medicine , lymphoblastic leukemia , cohort , acute lymphocytic leukemia , oncology , leukemia , pediatrics , biology , astrobiology

The safety and efficacy of blinatumomab, a CD19/CD3 bispecific T-cell engager (BiTE®) molecule, was evaluated in an expansion cohort of the phase 1b/2 study (NCT02412306) in Japanese adult (n = 14) and pediatric (n = 17) patients with relapsed/refractory Philadelphia-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research